Asymchem Laboratories Tianjin CoASLTY 72 EBITDA Margin % is 18.67% as of Mar. 2026, which is 40% below its 10-year median of 30.87. GuruFocus rates ASLTY with a GF Score™ of 72/100 and a GF Value™ of $4.52 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 945 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks better than 81.38% on this metric.
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Asymchem Laboratories Tianjin Co EBITDA Margin % Related Terms
Asymchem Laboratories Tianjin Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co EBITDA Margin % Chart
ASLTY vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co (ASLTY) has a EBITDA Margin % of 18.67% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Asymchem Laboratories Tianjin Co and its competitors. This is 40% below median its historical median of 30.87. Over the past decade, Asymchem Laboratories Tianjin Co's EBITDA Margin % has ranged from 18.40 to 39.76. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #176 out of 945 companies in the Biotechnology industry, placing it in the top 18.6%.
Is Asymchem Laboratories Tianjin Co's EBITDA Margin % too high?
Asymchem Laboratories Tianjin Co's current EBITDA Margin % of 18.67% is 40% below median its 10-year median of 30.87. Over the past 10 years, this metric has ranged from a low of 18.40 to a high of 39.76. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #176 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #176 out of 945 companies for EBITDA Margin %. This places Asymchem Laboratories Tianjin Co in the top 19% of its industry — outperforming the majority of peers. Historically, Asymchem Laboratories Tianjin Co's own EBITDA Margin % has ranged from 18.40 to 39.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Asymchem Laboratories Tianjin Co and its competitors. Asymchem Laboratories Tianjin Co's current EBITDA Margin % is 18.67%, which is 40% below median its own 10-year median of 30.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $6.37 — trading 40.9% above its estimated fair value. The current EBITDA Margin % is 18.67%, which is 40% below median its 10-year median of 30.87. Asymchem Laboratories Tianjin Co's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current EBITDA Margin % is 18.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $6.37 is trading 40.9% above its estimated GF Value™ of $4.52.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
EBITDA Margin %: 18.67% (40% below median its 10-year median of 30.87)
GF Value™: $4.52 vs. price of $6.37 (40.9% above fair value)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Business Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
72GF Score
Get the complete analysis for ASLTY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
